Tremelimumab
Tremelimumab
Immunoglobulin G2, anti-(human CTLA-4 (antigen)) (human monoclonal CP-675206 clone 11.2.1 heavy chain), disulfide with human monoclonal CP-675206 clone 11.2.1 light chain, dimer
Stoffgruppe
Antineoplastisches Mittel (Checkpoint-Inhibitor)
Halbwertszeit
ca. 14,2 Tage
Präparate